|8th May 2020||Marco Taglietti||6,000||Conversion of derivative||$0.00|
|12th December 2019||Marco Taglietti||166,667||Open or private purchase||$0.90||$150,000.30|
|21st August 2019||Marco Taglietti||9,500||Open or private purchase||$1.11||$10,545.00|
|20th August 2019||Marco Taglietti||500||Open or private purchase||$1.11||$555.00|
|15th August 2019||Marco Taglietti||10,015||Open or private purchase||$1.01||$10,115.15|
|17th April 2019||Marco Taglietti||25,000||Open or private purchase||$1.63||$40,750.00|
|15th February 2019||Scott Sukenick||100,000||Grant/award etc.||$0.00|
|15th February 2019||Gonzalez David Angulo||150,000||Grant/award etc.||$0.00|
|15th February 2019||Eric Francois||125,000||Grant/award etc.||$0.00|
|10th January 2019||Marco Taglietti||25,000||Open or private purchase||$0.69||$17,250.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
SCYNEXIS, Inc. is a biotechnology company. It engages in the development of novel oral and intravenous triterpenoid antifungal.